Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.58 |
| ▸ | PDE2A | O00408 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 10/20 | 0.54 |
| ▸ | APP | P05067 | 6/20 | 0.54 |
| ▸ | PDE5A | O76074 | 2/20 | 0.52 |
| ▸ | BCHE | P06276 | 5/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.44 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3997049 | 0.91 | ACHE (0.55) | PDE3BPDE3APDE2AACHEAPP | |
| SCHEMBL3995364 | 0.91 | PDE3B (0.49) | PDE3BPDE3APDE2AACHEAPP | |
| SCHEMBL4004387 | 0.90 | PDE3B (0.48) | PDE3BPDE3APDE2AACHEAPP | |
| SCHEMBL3998126 | 0.89 | PDE3B (0.48) | PDE3BPDE3APDE2AACHEAPP | |
| SCHEMBL4000391 | 0.88 | PDE3B (0.54) | PDE3BPDE3APDE2AACHEAPP | |
| SCHEMBL4003302 | 0.87 | PGK1 (0.48) | PDE3BPDE3APDE2AACHEAPP | |
| SCHEMBL3999059 | 0.86 | PDE3B (0.46) | PDE3BPDE3APDE2AACHEAPP | |
| SCHEMBL3997921 | 0.85 | ABCG2 (0.64) | PDE3BPDE3APDE2AABCG2MEN1 | |
| SCHEMBL3994293 | 0.84 | PGK1 (0.48) | PDE3BPDE3APDE2AACHEAPP | |
| SCHEMBL4003807 | 0.82 | PDE5A (0.52) | PDE3BPDE3APDE2AACHEAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022849-B2 | Quinazoline and pyrido[2,3-d]pyrimidine inhibitors of phosphodiesterase (PDE) 7 | BRISTOL-MYERS SQUIBB CO. (US) | 2006-04-04 | — | — | US | claimed |
| US-7601836-B2 | Pyrido[2,3-D]pyrimidine inhibitors of phosphodiesterase (PDE) 7 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-20060116516-A1 | Quinazoline and pyrido[2,3-d]pyrimidine inhibitors of phosphodiesterase (PDE) 7 | PITTS WILLIAM J | 2006-06-01 | — | — | US | disclosed |
| US-7022849-B2 | Quinazoline and pyrido[2,3-d]pyrimidine inhibitors of phosphodiesterase (PDE) 7 | BRISTOL-MYERS SQUIBB CO. (US) | 2006-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116516-A1 | Quinazoline and pyrido[2,3-d]pyrimidine inhibitors of phosphodiesterase (PDE) 7 | PDE3A, PDE3B, PDE2A | PDE3B 2/4885PDE3A 1/4885PDE2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.